Pfizer Stock Eyes 12% Upside Potential Driven by Robust Dividend Yield

Key Facts

As investors seek stable returns within the healthcare sector, Pfizer is emerging as a potential opportunity for both growth and value. According to reports, the stock shows a 12% upside potential with an average target price of $29.19. Additionally, the company offers a strong dividend yield of 6.61%, even as its payout ratio has climbed to 131.30%, reflecting a firm commitment to shareholder returns.

These positive projections come as the pharmaceutical industry navigates the post-pandemic landscape, with Pfizer competing alongside giants like Johnson & Johnson and Merck. Compared to its peers, Pfizer’s 6.61% yield significantly outpaces the sector average, with J&J yielding approximately 3.1% and Merck around 2.3% per market data. Analysts suggest that Pfizer's robust free cash flow remains a critical pillar supporting these payouts despite current operational pressures.

Traders should monitor current price levels, as PFE closed at $25.60 (close June 10, 2026), sitting roughly 14% below the projected target. Looking at the upcoming calendar, while there are no immediate company-specific catalysts, broader market sentiment will be influenced by upcoming US inflation data (CPI) next week, which typically impacts high-yield value stocks.